07 enero 2020

Surprise! There’s a Tumour in which Keytruda doesn’t Work. Este Fracaso de Merck en el intento de poder Tratar en Primera Línea el Cáncer de Pulmón Micricitico podría dar un Giro Descomunal a todo lo Establecido .



Merck's Keytruda falls short of rivals in 1 lung cancer type .



*********************************
Jan 07, 2020

Surprise! There’s a tumour in which Keytruda doesn’t work


The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Keytruda’s domination of the anti-PD-(L)1 market sometimes seems so comprehensive that it is surprising to see it flunk a clinical trial. Yesterday this is what happened, with the Keynote-604 study failing to show an overall survival benefit in first-line small-cell lung cancer.
The setback seems particularly galling because two competitors that are in desperate pursuit of Keytruda – Roche’s Tecentriq and Astrazeneca’s Imfinzi – have already succeeded in this tumour type. And the disparity has already seen one bank turn to scientific papers for an answer.
Citing a retrospective analysis published in Jama, Leerink has argued that in tumours characterised by poor PD-L1 expression and less fit patients – of which SCLC is one – there is evidence that PD-L1 inhibitors like Tecentriq and Imfinzi work better than PD-1-targeting drugs like Keytruda.
Yesterday’s disclosure that Keytruda had failed Keynote-604, and the earlier failure of Bristol-Myers Squibb’s Opdivo in Checkmate-451, appear to back such a hypothesis. A less sophisticated view holds that PD-1 drugs overall are better than PD-L1s, though this is massively skewed by the timing of study readouts.
Failed studies of anti-PD-(L)1 antibodies across various cancer types
KeytrudaOpdivoTecentriqImfinziBavencio
(anti-PD-1)(anti-PD-1)(anti-PD-L1)(anti-PD-L1)(anti-PD-L1)
UrothelialImvigor-211 (2L)
ColorectalImblaze-370 (3L)**
GastricKeynote-061 (2L)
Keynote-062 (1L)***
GlioblastomaCheckmate-143 (2L)
Checkmate-498 (1L)
Checkmate-548 (1L)
Javelin Gastric 300 (3L)
NSCLCCheckmate-026 (1L)Arctic (3L)
Mystic (1L)*
Javelin Lung 200 (2L)
SCLCKeynote-604 (1L)Checkmate-331 (2L)
Checkmate-451 (1L)*
Head & neckKeynote-040 (2L)Eagle (2L)*
OvarianJavelin Ovarian 100 (1L)
HepatocellularKeynote-240 (2L)Checkmate-459 (1L)
TNBCKeynote-119 (2L)
*CTLA-4 combo; **Cotellic combo; ***data inconclusive. 1L=1st line; 2L=2nd line; 3L=3rd line.
Tecentriq is already approved for first-line SCLC on the basis of the Impower-133 trial, and last year Imfinzi matched its result in the Caspian study (World Lung 2019 – Astra’s achievement in SCLC unlikely to be a game changer, September 9, 2019).
Both these anti-PD-L1 drugs showed 12 to 13 months of median overall survival, yielding around a 30% reduction in risk of death versus chemo alone. In Keynote-604 the absolute survival benefit has not been disclosed, but Merck said the 20% relative reduction in risk of death was insufficient to hit statistical significance.
There was a statistical benefit in progression-free survival, Keynote-604’s co-primary endpoint, but this is unlikely to be enough for approval given the availability of Tecentriq and Imfinzi’s Caspian result. Merck stock was off 2% this morning.
Irrespective of the first-line failure, Keytruda retains its third-line SCLC label with the backing of remission rates seen in the Keynote-028 and 159 studies.

And the front-line developments likely have little relevance for Pharmamar’s Zepsyre, which was recently filed for second-line SCLC and licensed to Jazz.

It is hard to gauge how much Keytruda could lose in sales; EvaluatePharma’s sales by indication consensus forecasts shows $748m of 2024 revenue coming from SCLC, but it is not clear how much of this comprises first-line use. Keytruda’s next significant test is the Keynote-355 readout in first-line triple-negative breast cancer.


Selected first-line SCLC trials
DrugCompanyStudySettingmOS result
OpdivoBristol-Myers SquibbCheckmate-451*Monotherapy, vs placebo10.4mth vs 9.6mth (HR=0.84, failed)
+ Yervoy, vs placebo9.2mth vs 9.6mth (HR=0.92, failed)
TecentriqRocheImpower-133On top of chemo, vs chemo12.3mth vs 10.3mth (HR=0.70, p=0.007)
ImfinziAstrazenecaCaspianOn top of chemo, vs chemo13.0mth vs 10.3mth (HR=0.73, p=0.005)
+ tremelimumab + chemo, vs chemoDue 2020
KeytrudaMerck & CoKeynote-604On top of chemo, vs chemo(HR=0.80, failed)
*First-line maintenance setting.